AP NEWS

INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference

December 4, 2018

-Voting begins today: Click here to cast your vote-

LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease , today announced that the Company has been nominated for the Buzz of BIO Contest, recognizing the most innovative companies at the 2019 CEO & Investor Conference. INmune Bio was nominated in the public company category, for its ground-breaking work in reprogramming the innate immune system to reverse chronic inflammation, an emerging approach to treating serious illnesses and diseases, including multiple cancer types.

Voting officially begins today, December 4, 2018 at 9:00 a.m. Eastern Time and runs through Thursday, December 6, 2018 at 5:00 p.m. Eastern Time.

Why Vote for INmune

1. INmune Bio is focused on reprogramming the innate immune system to reverse chronic inflammation, an unrecognized but pervasive disease, with clinical programs in cancer and beyond. 2. The lead oncology asset, INB03 targets myeloid derived suppressor cells (MDSC), the most important cell of the tumor microenvironment that is responsible for resistance to immunotherapy including checkpoint inhibitors (CPI). The goal is to eliminate resistance to CPI in patients with biomarkers of chronic inflammation including elevated MDSC. INB03, also known as XPro1595, has been studied in other therapeutic areas with more than 50 publications. 3. INKmune™, a novel biologic that activates the patient’s Natural Killer (NK) cells to attack cancer cells, is being developed for the treatment of relapse refractory ovarian cancer and high-risk myelodysplastic syndromes (MDS); both trials are expected to begin during 2019.

“We are excited about our nomination for the Buzz of Bio conference in the public company category, as this recognition underscores the potential importance of our emerging science to fight serious disease and illness, including cancer,” said RJ Tesi, M.D., CEO and Co-Founder of the Company. “We encourage participation in the voting process, as biotechnology is founded on innovation grounded in scientific curiosity, and this award speaks to the heart of the industry’s mission.”

To cast your vote, click here.

About INmune Bio, Inc.

INmune Bio, Inc. is a private clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack developing disease INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors. To learn more, please visit www.inmunebio.com.

INmune Bio Contact:David Moss, CFO(858) 964-3720dmoss@inmunebio.com www.inmunebio.com

Investors:LHA Investor RelationsMiriam Weber MillerSenior Vice President(212) 838-3777 mmiller@lhai.com

Ascent Investor RelationsTina XiaoPresident (917) 609-0333 tina.xiao@ascent-ir.com

AP RADIO
Update hourly